AACR logo

怎么爬墙ins

Visit the COVID-19 & Cancer Resource Center to access all content related to COVID-19 that is now freely available from across the AACR Journals.

Read The Best of the AACR Journals, a collection of the most-cited articles across the AACR Journals. Each journal’s section includes the five most-cited research articles based on the total number of citations from date of publication through January 2023. Learn about the authors behind these impactful papers in the 手机翻国外网站教程.

Read the inaugural issue of the latest AACR Journal, Blood Cancer Discovery, which provides a critical outlet for high-impact basic, translational and clinical research on all disease subtypes of leukemia, lymphoma, myeloma, and associated diseases.

手机翻国外网站教程

Keep up with “what’s new” by following the AACR Journals on Twitter:

@BCD_AACR: Blood Cancer Discovery
手机怎么登录国外网: Cancer Discovery
@CEBP_AACR: Cancer Epidemiology, Biomarkers & Prevention
@CIR_AACR: 手机怎么翻外国网络
@CAPR_AACR: Cancer Prevention Research
@CR_AACR: Cancer Research
@CCR_AACR: Clinical Cancer Research
@MCR_AACR: Molecular Cancer Research
手机怎么登录国外网: Molecular Cancer Therapeutics

怎么爬墙ins

手机浏览国外网站的方法
will provide a critical outlet for high-impact basic, translational, and clinical research on all disease subtypes of leukemia, lymphoma, myeloma, and associated diseases. Studies published in Blood Cancer Discovery will describe mechanisms underlying disease biology; diagnostic and therapeutic development; and translation of these data into clinical trials.

Cancer Discovery
publishes high-impact articles featuring major advances in research and clinical trials. Topics span the spectrum of cancer research and medicine from the laboratory to the clinic to epidemiologic studies. The journal also publishes News and Research Watch sections.

Cancer Epidemiology, Biomarkers & Prevention
publishes articles featuring population-based research on cancer etiology, prevention, surveillance, survivorship, and cancer health disparities—with a particular focus on articles with a transdisciplinary approach.

Cancer Immunology Research
publishes outstanding original articles reporting major advances in cancer immunology that span the discipline from basic investigations in host-tumor interactions to developmental therapeutics in model systems, early translational studies in patients, and late-stage clinical trials.

Cancer Prevention Research
publishes articles that focus on cancer prevention, preclinical, clinical, and translational research, with special attention given to molecular discoveries and an emphasis on building a translational bridge between the basic and clinical sciences.

Cancer Research
publishes original studies, reviews, and opinion pieces offering significance and broad impact to a diverse audience. Cancer Research seeks manuscripts that offer pathobiological and translational impact to inform the personal, clinical, and societal problems posed by cancer. The main scope of the journal is captured in its primary subsections: Genome and Epigenome, Metabolism and Chemical Biology, Molecular Cell Biology, Tumor Biology and Immunology, Translational Science, Convergence and Technologies, and Population and Prevention Science.

Clinical Cancer Research
publishes articles that focus on innovative clinical and translational research bridging the laboratory and the clinic. Topics include targeted therapies; mechanisms of drug sensitivity and resistance; pharmacogenetics and pharmacogenomics; personalized medicine; immunotherapy; gene therapy; diagnostic biomarkers; innovative imaging, and clinical genetics.

Molecular Cancer Research
publishes articles featuring novel, basic cancer research discoveries that prioritize broad molecular and cellular processes. Areas of emphasis include cell cycle and senescence; cell death and survival; chromatin, gene and RNA regulation; DNA damage and repair; genomics; oncogenes and tumor suppressors; and signal transduction.

Molecular Cancer Therapeutics
publishes articles on the discovery and preclinical development of novel therapeutic agents for oncology, preclinical studies of approved therapeutics, mechanisms of drug action, mechanism of drug resistance, biomarkers of drug response, novel models and technologies, and occasional drug toxicity mechanisms.